Patent application number | Description | Published |
20090155282 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 06-18-2009 |
20090156790 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 06-18-2009 |
20090175887 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 07-09-2009 |
20090240038 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 09-24-2009 |
20100111979 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 05-06-2010 |
20100273858 | COMPOSITIONS COMPRISING STAT5 SIRNA AND METHODS OF USE THEREOF - The present invention provides nucleic acid molecules that inhibit STAT5 expression. Methods of using the nucleic acid molecules are also provided. | 10-28-2010 |
20100286241 | COMPOSITIONS COMPRISING K-RAS SIRNA AND METHODS OF USE - The present invention provides nucleic acid molecules that inhibit K-ras expression. Methods of using the nucleic acid molecules are also provided. | 11-11-2010 |
20100298409 | COMPOSITIONS COMPRISING STAT3 SIRNA AND METHODS OF USE THEREOF - The present invention provides nucleic acid molecules that inhibit STAT3 expression. Methods of using the nucleic acid molecules are also provided. | 11-25-2010 |
20110046067 | COMPOSITIONS COMPRISING HUMAN EGFR-siRNA AND METHODS OF USE - The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided. | 02-24-2011 |
20110053861 | COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-KB) SIRNA AND METHODS OF USE - The present invention provides siRNA nucleic acid molecules that inhibit NF-kappaB expression. Methods of using the nucleic acid molecules are also provided. | 03-03-2011 |
20110053862 | COMPOSITIONS COMPRISING SURVIVIN SIRNA AND METHODS OF USE THEREOF - The present invention provides siRNA nucleic acid molecules that inhibit survivin expression. Methods of using the nucleic acid molecules are also provided. | 03-03-2011 |
20110065644 | COMPOSITIONS COMPRISING HUMAN PCSK9 AND APOLIPOPROTEIN B SIRNA AND METHODS OF USE - The present invention provides siRNA nucleic acid molecules that inhibit PCSK9 or apolipoprotein B expression. Methods of using the nucleic acid molecules are also provided. | 03-17-2011 |
20110105588 | COMPOSITIONS COMPRISING NOTCH1 SIRNA AND METHODS OF USE THEREOF - The present invention provides siRNA nucleic acid molecules that inhibit Notch1 expression. Methods of using the nucleic acid molecules are also provided. | 05-05-2011 |